YAP/miR-524-5p axis negatively regulates TXNIP expression to promote chondrosarcoma cell growth
Ri-Xu Liu1, Wang Tang1, Bo-Yuan Zheng1
1Center for Joint Surgery and Sports Medicine, The First Affiliated Hospital, Jinan University, Guangzhou, 510630, China; Institute of Orthopedic Diseases & the Bone and Joint Disease Institute of Guangdong-Hong Kong-Macao Greater Bay Area, Jinan University, Guangzhou, 510630, China.
Abstract:
Chondrosarcoma (CHS) is the second most common bone malignant tumor and currently has limited treatment options. We have recently demonstrated that thioredoxin interacting protein (TXNIP) plays a crucial role in the oncogenesis of bone sarcoma, yet its implication in CHS is underdetermined. In the present study, we first found that knockdown of TXNIP promotes the proliferation of CHS cell largely through increasing their glycolytic metabolism, which is well-known as Warburg effect for providing energy. Consistent with our previous report that YAP is fundamental for CHS cell growth, herein we revealed that YAP functioned as an upstream molecule of TXNIP, and that YAP negatively regulated TXNIP mRNA and protein expression both in vitro and in vivo. Mechanistically, although knockdown of YAP upregulated both the nuclear and cytoplasmic TXNIP expression, we did not observe any obvious interaction between YAP and TXNIP; instead, miRNA-524-5p was demonstrated to be required for YAP-regulated TXNIP expression and thus controlling CHS cell growth. Together, our study reveals that TXNIP is a tumor suppressor in terms of CHS, and that the YAP/miRNA-524-5p/TXNIP signaling axis may provide a novel clue for CHS targeted therapy.
Insights
Thioredoxin interacting protein (TXNIP) acts as a tumor suppressor in chondrosarcoma (CHS). The YAP/miRNA-524-5p/TXNIP pathway regulates CHS cell growth and offers potential therapeutic targets.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Chondrosarcoma (CHS) is a common bone cancer with limited treatment options.
- Thioredoxin interacting protein (TXNIP) is implicated in bone sarcoma oncogenesis.
- The role of TXNIP in CHS progression is currently under investigation.
Purpose of the Study:
- To investigate the role of TXNIP in chondrosarcoma (CHS) development.
- To elucidate the regulatory mechanisms of TXNIP expression in CHS.
- To identify potential therapeutic targets for CHS.
Main Methods:
- TXNIP knockdown in CHS cells to assess proliferation and metabolism.
- Yeast-two hybrid assays and co-immunoprecipitation to study YAP-TXNIP interaction.
- Quantitative real-time PCR and Western blotting to analyze gene and protein expression.
- In vitro and in vivo experiments to validate findings.
Main Results:
- TXNIP knockdown enhanced CHS cell proliferation by increasing glycolytic metabolism (Warburg effect).
- Yeast-two hybrid assays revealed YAP functions as an upstream regulator of TXNIP.
- YAP negatively modulated TXNIP mRNA and protein expression both in vitro and in vivo.
- miRNA-524-5p was identified as a crucial mediator in the YAP-regulated TXNIP expression pathway.
- No direct interaction was observed between YAP and TXNIP.
Conclusions:
- TXNIP functions as a tumor suppressor in chondrosarcoma.
- The YAP/miRNA-524-5p/TXNIP signaling axis plays a significant role in CHS cell growth.
- This pathway represents a potential novel therapeutic strategy for chondrosarcoma.
More Related Videos
10:32Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs
Published on: December 19, 2019
09:55All-optical Mechanobiology Interrogation of Yes-associated Protein in Human Cancer and Normal Cells using a Multi-functional System
Published on: December 20, 2021
Related Concept Videos
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
MicroRNAs
Induced Pluripotent Stem Cells
Somatic...
Negative Regulator Molecules
